Abstract 16077: Homoarginine Predicts All-Cause Mortality in the Dallas Heart Study
Background: Homoarginine is a non-proteinogenic amino acid. It is structurally related to L-arginine and can be found in pea varieties. Homoarginine has been proposed to have anti-atherosclerotic effects by serving as a weak substrate of nitric oxide synthase (NOS). Lower plasma homoarginine concentrations were found to be associated with cardiovascular and all-cause mortality in patients subjected to coronary angiography in the Ludwigshafen Risk and Cardiovascular Health (LURIC) cohort. The aim of the present study was to elucidate the predictive value of homoarginine in the general population.
Methods and Results: Homoarginine plasma concentrations were determined in 3514 subjects of the community-based Dallas Heart Study (DHS) using a validated LC-MS/MS method. The median mortality follow-up was 8.4 years. Median homoarginine plasma concentration was 2.80 (IQR: 2.14-3.54) µmol/L for the entire cohort, with different medians in the subsets of Black vs. non-Black individuals (2.93; 2.25-3.67 µmol/L vs. 2.68; 2.04-3.43 µmol/L; p<0.0001). In multivariable Cox regression analyses adjusted for traditional CV risk factors, homoarginine was significantly and inversely associated with all-cause mortality (HR 0.74 for homoarginine above the median, 95% CI 0.54, 0.99) and with cerebrovascular endpoints (stroke/TIA/revascularization) (HR 0.44; 0.25, 0.77).
Conclusion: In the general population, low plasma homoarginine is an independent predictor for all-cause mortality and cerebrovascular events, suggesting a potential role for homoarginine as prognostic marker and, with further evaluation, as potential therapeutic strategy. Figure: Kaplan-Meier Curve for plasma homoarginine above/below the median (2.80 µmol/L; log-rank p=0.004).
- © 2012 by American Heart Association, Inc.